Gastric cancer

Elizabeth Smyth(National Health Service), Florian Lordick(Leipzig University), Heike I. Grabsch(University of Leeds), Magnus Nilsson(Karolinska University Hospital), Nicole C.T. van Grieken(Cancer Center Amsterdam)

The Lancet

August 1, 2020

10.1016/s0140-6736(20)31288-5

Cited by 4,829

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Genome-wide cell-free DNA fragmentation in patients with cancer

|Nature|2019|1.5k

Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer

|Nature Medicine|2019|1.4k

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2022|1.4k

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

|Journal of Clinical Oncology|2020|1.2k